© Reuters. FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo
(Reuters) – The U.S. Supreme Court on Thursday turned down Novartis Pharmaceuticals Corp’s bid to block the launch of generic versions of the company’s blockbuster multiple sclerosis drug Gilenya in a dispute with China’s HEC Pharm Co Ltd and other generic drugmakers.
Novartis had asked the justices to stay a lower court’s ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company’s third highest-selling drug last year with $2.8 billion in sales.
Be the first to comment